<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838043</url>
  </required_header>
  <id_info>
    <org_study_id>6016312</org_study_id>
    <nct_id>NCT02838043</nct_id>
  </id_info>
  <brief_title>The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients</brief_title>
  <official_title>The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lallemand Health Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <brief_summary>
    <textblock>
      This study will be an 8-week open-label pilot study examining subjective and objective&#xD;
      changes in mood, anxiety, cognition, and sleep before and after the introduction of a&#xD;
      probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum in 10&#xD;
      treatment-naïve participants diagnosed with major depressive disorder (MDD). In order to&#xD;
      examine the full composition of the micro biome, the investigators will also be collecting&#xD;
      and analyzing fecal samples as well as blood samples to examine changes in plasma levels of&#xD;
      inflammatory markers, 5-HT, and tryptophan in order to look at possible underlying mechanisms&#xD;
      of any changes seen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mood</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mood will be assessed with the Montgomery-Asberg Depression Rating Scale (MADRS) with a cut-off score of 12 indicating remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>8 weeks</time_frame>
    <description>Anxiety will be assessed with the Generalized Anxiety Disorder Scale (GAD-7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cognition will be assess with the Digit Symbol Substitution Test (DSST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>8 weeks</time_frame>
    <description>Sleep will be assessed objectively using a polysomnogram to look at changes electrophysiological sleep architecture after 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma will be analyzed to look at levels of inflammatory markers to see whether there is a decrease after 8 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Depression</condition>
  <condition>Depressive Symptoms</condition>
  <arm_group>
    <arm_group_label>Participant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will be experimental and receive Probio'Stick.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probio'Stick</intervention_name>
    <description>A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum</description>
    <arm_group_label>Participant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Major Depressive Disorder (MDD) by Mini International Neuropsychiatric&#xD;
             Interview (MINI)&#xD;
&#xD;
          2. Current depressive episode with a MADRS score of ≥ 20&#xD;
&#xD;
          3. Males and females between ages 18 and 65&#xD;
&#xD;
          4. Able to understand and comply with the requirements of the study&#xD;
&#xD;
          5. Provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any antidepressant drug&#xD;
&#xD;
          2. Use of any antibiotic drug in the past 4 weeks (may be eligible to participate after a&#xD;
             1-month washout period)&#xD;
&#xD;
          3. Use of any sleep medication in the past 4 weeks (may be eligible to participate after&#xD;
             a 1-month washout period)&#xD;
&#xD;
          4. Milk, yeast, or soy allergy&#xD;
&#xD;
          5. History of alcohol or substance abuse in the past 6 months&#xD;
&#xD;
          6. Daily use of probiotic product in the past 2 weeks (may be eligible to participate&#xD;
             after a 2-week washout period)&#xD;
&#xD;
          7. Use of any type of laxative&#xD;
&#xD;
          8. Consumption of products fortified in probiotics&#xD;
&#xD;
          9. Severely suicidal&#xD;
&#xD;
         10. Experiencing psychosis or bipolar episode&#xD;
&#xD;
         11. History of epilepsy or uncontrolled seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roumen Milev, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Care - Mental Health Services</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Roumen Milev</investigator_full_name>
    <investigator_title>Psychiatrist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

